The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Open accessAbstract
Cancer cells have metabolic dependencies that distinguish them from their normal counterparts. Among these dependencies is an increased use of the amino acid glutamine to fuel anabolic processes. Indeed, the spectrum of glutamine-dependent tumours and the mechanisms whereby glutamine supports cancer metabolism remain areas of active investigation. Here we report the identification of a non-canonical pathway of glutamine use in human pancreatic ductal adenocarcinoma (PDAC) cells that is required for tumour growth. Whereas most cells use glutamate dehydrogenase (GLUD1) to convert glutamine-derived glutamate into α-ketoglutarate in the mitochondria to fuel the tricarboxylic acid cycle, PDAC relies on a distinct pathway in which glutamine-derived aspartate is transported into the cytoplasm where it can be converted into oxaloacetate by aspartate transaminase (GOT1). Subsequently, this oxaloacetate is converted into malate and then pyruvate, ostensibly increasing the NADPH/NADP(+) ratio which can potentially maintain the cellular redox state. Importantly, PDAC cells are strongly dependent on this series of reactions, as glutamine deprivation or genetic inhibition of any enzyme in this pathway leads to an increase in reactive oxygen species and a reduction in reduced glutathione. Moreover, knockdown of any component enzyme in this series of reactions also results in a pronounced suppression of PDAC growth in vitro and in vivo. Furthermore, we establish that the reprogramming of glutamine metabolism is mediated by oncogenic KRAS, the signature genetic alteration in PDAC, through the transcriptional upregulation and repression of key metabolic enzymes in this pathway. The essentiality of this pathway in PDAC and the fact that it is dispensable in normal cells may provide novel therapeutic approaches to treat these refractory tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, depending on the tissue of origin, cancer cells use various routes of glutamine metabolism. Some have been shown to require an exogenous glutamine supply for malignant proliferation [71,72], whereas others do not [73] and can synthesize it de novo [74].”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [73]
In the citing paper
“For instance, KRAS-dependent upregulation of Glutamate Oxaloacetate Transaminase 1,2. (GOT) expression in pancreatic cancer facilitates production of aspartate for nucleotide biosynthesis, and allows NADPH generation via ME157,58 (Fig 2).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [57]
In the citing paper
“Mouse PDAC tumors driven by mutant Kras also experience metabolic alteration and are dependent on glucose and glutamine (73, 77).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [77]
In the citing paper
“combining inhibition of glycolysis with blockade of KRAS effector signaling pathways has shown efficacy in culture and xenograft models197”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [197]
In the citing paper
“metabolic inhibition approaches combined with RAS pathway inhibitors have shown strong pre-clinical data and are currently in clinical trials197,224,225”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [197]
In the citing paper
“However, under normal and glucose-replete conditions, transamination is the dominant reaction that drives glutamine anaplerosis in cultured cells (79, 80, 81, 82).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Self-citationSpencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationWise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,004
Zhu, H., Zou, G., Wang, N., Zhuang, M., Xiong, W., & Huang, G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615557114 · Cited by 133
Alternative fuels for cancer cells
Keenan, M. M., & Chi, J.-T. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000104 · Cited by 131
Glutamate enrichment as new diagnostic opportunity in breast cancer
Budczies, J., Pfitzner, B. M., Győrffy, B., Winzer, K., Radke, C., Dietel, M., Fiehn, O., & Denkert, C. (2014) · International Journal of Cancer · doi:10.1002/ijc.29152 · Cited by 133
The epithelial to mesenchymal transition in pancreatic cancer: A systematic review
Beuran, M., Negoi, I., Paun, S. C., Ion, D. A., Bleoţu, C., Negoi, R. I., & Hostiuc, S. (2015) · Pancreatology · doi:10.1016/j.pan.2015.02.011 · Cited by 133
Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
Hernandez-Davies, J. E., Tran, T. Q., Reid, M. A., Rosales, K. R., Lowman, X. H., Pan, M., Moriceau, G., Yang, Y., Wu, J., Lo, R. S., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0581-2 · Cited by 131
Kong, C., Li, Y., Liu, Z., Ye, J., Wang, Z., Zhang, L., Kong, W., Liu, H., Liu, C., Pang, H., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b08246 · Cited by 127
Targeting pancreatic cancer metabolic dependencies through glutamine antagonism
Encarnación-Rosado, J., Sohn, A. S. W., Biancur, D. E., Lin, E. Y., Osorio-Vasquez, V., Rodrick, T. C., González-Baerga, D., Zhao, E., Yokoyama, Y., Simeone, D. M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00647-3 · Cited by 138
Self-citationChakrabarti, G., Moore, Z., Luo, X., Ilcheva, M., Ali, A., Padanad, M. S., Zhou, Y., Xie, Y., Burma, S., Scaglioni, P. P., et al. (2015) · Cancer & Metabolism · doi:10.1186/s40170-015-0137-1 · Cited by 131
Self-citationOncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer
Hutton, J. E., Wang, X., Zimmerman, L. J., Slebos, R. J. C., Trenary, I. A., Young, J. D., Li, M., & Liebler, D. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058925 · Cited by 139
Self-citationZhao, Y., Feng, X., Chen, Y., Selfridge, J. E., Gorityala, S., Du, Z., Wang, J. M., Hao, Y., Cioffi, G., Conlon, R. A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0600 · Cited by 130
Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression
Hu, T., Shukla, S. K., Vernucci, E., He, C., Wang, D., King, R. J., Jha, K., Siddhanta, K., Mullen, N. J., Attri, K. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.045 · Cited by 131
Yang, Y., Gabra, M. B. I., Hanse, E. A., Lowman, X. H., Tran, T. Q., Li, H., Milman, N., Liu, J., Reid, M. A., Locasale, J. W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08759-0 · Cited by 129
Glutamine Metabolism Controls Chondrocyte Identity and Function
Stegen, S., Rinaldi, G., Loopmans, S., Stockmans, I., Moermans, K., Thienpont, B., Fendt, S., Carmeliet, P., & Carmeliet, G. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.05.001 · Cited by 130
Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context
Kerk, S. A., Lin, L., Myers, A. L., Sutton, D. J., Andren, A., Sajjakulnukit, P., Zhang, L., Zhang, Y., Jiménez, J. A., Nelson, B. S., et al. (2022) · eLife · doi:10.7554/elife.73245 · Cited by 108
Self-citationAmplification of USP13 drives ovarian cancer metabolism
Han, C., Yang, L., Choi, H. H., Baddour, J., Achreja, A., Liu, Y., Li, Y., Li, J., Wan, G., Huang, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms13525 · Cited by 127
Koundinya, M., Sudhalter, J., Courjaud, A., Lionne, B., Touyer, G., Bonnet, L., Menguy, I., Schreiber, I., Perrault, C., Vougier, S., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.03.005 · Cited by 123
SIRT2‐dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases
Wang, B., Ye, Y., Yang, X. P., Liu, B., Wang, Z., Chen, S., Jiang, K., Zhang, W., Jiang, H., Mustonen, H. K., et al. (2020) · EMBO Reports · doi:10.15252/embr.201948183 · Cited by 125
Wei, F., Wang, D., Wei, J., Tang, N., Tang, L. M., Xiong, F., Guo, C. J., Zhou, M., Li, X., Li, G., et al. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03581-0 · Cited by 128
Wong, C. C., Qian, Y., Li, X., Xu, J., Kang, W., TONG, J. H. M., To, K., Ye, J., Li, W., Chen, H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.07.011 · Cited by 129
Recent insights into the biology of pancreatic cancer
Yao, W., Maitra, A., & Ying, H. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102655 · Cited by 127
Self-citationMuscle-specific 4E-BP1 signaling activation improves metabolic parameters during aging and obesity
Tsai, S., Sitzmann, J. M., Dastidar, S. G., Rodriguez, A. A., Vu, S. L., McDonald, C. E., Academia, E. C., O’Leary, M. N., Ashe, T. D., La Spada, A. R., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77361 · Cited by 126
Biological determinants of radioresistance and their remediation in pancreatic cancer
Seshacharyulu, P., Baine, M. J., Souchek, J. J., Menning, M., Kaur, S., Yan, Y., Ouellette, M. M., Jain, M., Lin, C. H., & Batra, S. K. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.02.003 · Cited by 127
Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
Pelosi, E., Castelli, G., & Testa, U. (2017) · Biomedicines · doi:10.3390/biomedicines5040065 · Cited by 128
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer
Brunton, H., Caligiuri, G., Cunningham, R., Upstill‐Goddard, R., Bailey, U., Garner, I., Nourse, C., Dreyer, S. B., Jones, M. D., Moran‐Jones, K., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107625 · Cited by 121
Mai, Z., Zhong, J., Zhang, J., Chen, G., Tang, Y., Ma, W., Li, G., Feng, Z., Li, F., Liang, X., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c11037 · Cited by 124
Wnt Signaling in Cancer Metabolism and Immunity
El‐Sahli, S., Xie, Y., Wang, L., & Liu, S. (2019) · Cancers · doi:10.3390/cancers11070904 · Cited by 123
Glucose Metabolism in Pancreatic Cancer
Liang, Y., Raj, P. S., Yao, W., & Ying, H. (2019) · Cancers · doi:10.3390/cancers11101460 · Cited by 127
Self-citationGlutamine Metabolism in Cancer
Li, T., Copeland, C., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_2 · Cited by 134
Deng, S.-J., Chen, H., Zeng, Z., Deng, S., Zhu, S., Zeng, Y., He, C., Liu, M., Huang, K., Zhong, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0419 · Cited by 120
Targeting cancer cell metabolism in pancreatic adenocarcinoma
Cohen, R., Neuzillet, C., Tijeras‐Raballand, A., Faivre, S. J., Gramont, A. D. E., & Raymond, É. (2015) · Oncotarget · doi:10.18632/oncotarget.4160 · Cited by 119
The complex landscape of pancreatic cancer metabolism
Sousa, C. M., & Kimmelman, A. C. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu097 · Cited by 125
Self-citationAGC1/2, the mitochondrial aspartate-glutamate carriers
Amoêdo, N. D., Punzi, G., Obre, É., Lacombe, D., Grassi, A., Pierri, C. L., & Rossignol, R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.04.011 · Cited by 128
Liao, J., Liu, P., Hou, G., Shao, J., Yang, J., Liu, K., Lu, W., Wen, S., Hu, Y., & Huang, P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0623-x · Cited by 119
Cancer metabolism: New insights into classic characteristics
Kato, Y., Maeda, T., Suzuki, A., & Baba, Y. (2017) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2017.08.003 · Cited by 121
Mathew, R., Khor, S., Hackett, S. R., Rabinowitz, J. D., Perlman, D. H., & White, E. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.07.019 · Cited by 120
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions
Xu, X. J., Meng, Y., Li, L., Xu, P., Wang, J., Li, Z., & Bian, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00961 · Cited by 118
Metabolic Regulation of Redox Balance in Cancer
Purohit, V., Simeone, D. M., & Lyssiotis, C. A. (2019) · Cancers · doi:10.3390/cancers11070955 · Cited by 121
Self-citationJain, A., & Zoncu, R. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101481 · Cited by 122
Hollinshead, K. E. R., Parker, S. J., Eapen, V. V., Encarnación-Rosado, J., Sohn, A. S. W., Oncu, T., Cammer, M., Mancias, J. D., & Kimmelman, A. C. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108231 · Cited by 118
Self-citationErstad, D. J., Sojoodi, M., Taylor, M. S., Ghoshal, S., Razavi, A. A., Graham‐O'Regan, K. A., Bardeesy, N. M., Ferrone, C. R., Lanuti, M. D., Caravan, P. D., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.034793 · Cited by 124
Self-citationFerroptosis: Final destination for cancer?
Zeng, Y., Liu, W., Zhuo, Q., Hu, Q., Liu, M., Sun, Q., Zhang, Z., Fan, G., Xu, W., Ji, S., et al. (2020) · Cell Proliferation · doi:10.1111/cpr.12761 · Cited by 116
Kras as a key oncogene and therapeutic target in pancreatic cancer
Collins, M. A., & di Magliano, M. P. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2013.00407 · Cited by 114
Toda, K., Kawada, K., Iwamoto, M., Inamoto, S., Sasazuki, T., Shirasawa, S., Hasegawa, S., & Sakai, Y. (2016) · Neoplasia · doi:10.1016/j.neo.2016.09.004 · Cited by 113
A nexus for cellular homeostasis: the interplay between metabolic and signal transduction pathways
Gomes, A. P., & Blenis, J. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.12.007 · Cited by 112
Amino acid management in cancer
Tsun, Z.-Y., & Possemato, R. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.08.002 · Cited by 120
Jeong, S. M., Hwang, S., & Seong, R. H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.023 · Cited by 112
Bioenergetic-active materials enhance tissue regeneration by modulating cellular metabolic state
Liu, H., Du, Y., St‐Pierre, J., Bergholt, M. S., Autefage, H., Wang, J., Cai, M., Yang, G., Stevens, M. M., & Zhang, S. (2020) · Science Advances · doi:10.1126/sciadv.aay7608 · Cited by 114
Vučetić, M., Cormerais, Y., Parks, S. K., & Pouysségur, J. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00319 · Cited by 121
Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer
Nguyen, T. A., Kirsch, B. J., Asaka, R., Nabi, K., Quinones, A., Tan, J., Antonio, M. J., Camelo, F., Li, T., Nguyen, S. A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.036 · Cited by 111
Branched-chain amino acids sustain pancreatic cancer growth by regulating lipid metabolism
Lee, J. H., Cho, Y.-R., Kim, J. H., Kim, J.-W., Nam, H. Y., Kim, S. W., & Son, J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0350-z · Cited by 111
Self-citationHammel, P. R., Portales, F., Mineur, L., Metges, J., André, T., de la Fouchardière, C., Louvet, C., Hajbi, F. E., Faroux, R., Guimbaud, R., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.020 · Cited by 114
Porporato, P. E., Payen, V. L., Baselet, B., & Sonveaux, P. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2100-2 · Cited by 115
The Pleiotropic Effects of Glutamine Metabolism in Cancer
Bott, A. J., Maimouni, S., & Zong, W. (2019) · Cancers · doi:10.3390/cancers11060770 · Cited by 111
Current and future perspectives of functional metabolomics in disease studies–A review
Yan, M., & Xu, G. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.04.006 · Cited by 105
Li, Y., He, Y., Peng, J., Su, Z., Li, Z., Zhang, B., Ma, J., Zhuo, M., Zou, D., Liu, X., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00134-z · Cited by 108
Okazaki, A., Gameiro, P. A., Christodoulou, D. C., Laviolette, L. A., Schneider, M., Chaves, F. L., Stemmer-Rachamimov, A. O., Yazinski, S. A., Lee, R. E., Jr., Stephanopoulos, G. N., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87800 · Cited by 110
Yang, S., Hwang, S., Kim, M., Seo, S. B., Lee, J., & Jeong, S. M. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0089-1 · Cited by 108
Cross-Talk Between the Tumor Microenvironment, Extracellular Matrix, and Cell Metabolism in Cancer
Nazemi, M., & Rainero, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00239 · Cited by 110
O-GlcNAcylation promotes pancreatic tumor growth by regulating malate dehydrogenase 1
Zhu, Q., Zhou, H., Wu, L., Lai, Z., Geng, D., Yang, W., Zhang, J., Fan, Z., Qin, W., Wang, Y., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01085-5 · Cited by 107
State of the art and future directions of pancreatic ductal adenocarcinoma therapy
Neuzillet, C., Tijeras‐Raballand, A., Bourget, P., Cros, J. F., Couvelard, A., Sauvanet, A., Vullierme, M., Tournigand, C., & Hammel, P. R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.08.006 · Cited by 114
Brandi, J., Dando, I., Pozza, E. D., Biondani, G., Jenkins, R. E., Elliott, V., Park, K., Fanelli, G., Zolla, L., Costello, E., et al. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.10.002 · Cited by 106
Starve Cancer Cells of Glutamine: Break the Spell or Make a Hungry Monster?
Jiang, J., Srivastava, S., & Zhang, J. (2019) · Cancers · doi:10.3390/cancers11060804 · Cited by 108
Amino Acid Metabolism in Cancer Drug Resistance
Yoo, H.-C., & Han, J. M. (2022) · Cells · doi:10.3390/cells11010140 · Cited by 107
Liu, G., Zhu, J., Yu, M., Cai, C., Zhou, Y., Yu, M., Fu, Z., Gong, Y., Yang, B., Li, Y., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0500-6 · Cited by 104
Critical role for arginase 2 in obesity-associated pancreatic cancer
Zaytouni, T., Tsai, P.-Y., Hitchcock, D. S., DuBois, C. D., Freinkman, E., Lin, L., Morales‐Oyarvide, V., Lenehan, P. J., Wolpin, B. M., Mino-Kenudson, M. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00331-y · Cited by 106
Adamska, A., & Falasca, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i29.3222 · Cited by 107
Luo, X., Liu, J., Wang, H., & Lu, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104805 · Cited by 103
Chen, J., Zou, L., Lu, G. X., Grinchuk, O. V., Fang, L., Ong, D. S. T., Taneja, R., Ong, C. N., & Shen, H. (2022) · Cell Discovery · doi:10.1038/s41421-022-00406-1 · Cited by 107
Bajpai, R., Matulis, S. M., Wei, C., Nooka, A. K., Hollen, H. V., Lonial, S., Boise, L., & Shanmugam, M. (2015) · Oncogene · doi:10.1038/onc.2015.464 · Cited by 106
Exploring cancer metabolism using stable isotope-resolved metabolomics (SIRM)
Bruntz, R. C., Lane, A. N., Higashi, R. M., & Fan, T. W. ‐. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.776054 · Cited by 107
Regulation of Cancer Metabolism by Oncogenes and Tumor Suppressors
Iurlaro, R., León‐Annicchiarico, C. L., & Muñoz‐Pinedo, C. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-416618-9.00003-0 · Cited by 114
Truong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102
Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies
Xiao, Y., & Meierhofer, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153672 · Cited by 104
Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
Chen, R., Lai, L. A., Sullivan, Y., Wong, M., Wang, L., Riddell, J., Jung, L., Pillarisetty, V. G., Brentnall, T. A., & Pan, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-08436-6 · Cited by 92
Pancreatic cancer: Current research and future directions
Falasca, M., Kim, M., & Casari, I. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.01.001 · Cited by 101
The impact of oncogenic RAS on redox balance and implications for cancer development
Lim, J. K. M., & Leprivier, G. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2192-y · Cited by 106
The role of FAK in tumor metabolism and therapy
Zhang, J., & Hochwald, S. N. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.003 · Cited by 104
Philip, P. A., Buyse, M. E., Alistar, A. T., Lima, C. M. S. R., Luther, S., Pardee, T. S., & Cutsem, E. V. (2019) · Future Oncology · doi:10.2217/fon-2019-0209 · Cited by 101
Targeting glutamine metabolism slows soft tissue sarcoma growth
Lee, P., Malik, D. M., Perkons, N. R., Huangyang, P., Khare, S., Rhoades, S. D., Gong, Y.-Y., Burrows, M., Finan, J. M., Nissim, I., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14374-1 · Cited by 105
Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer
Liu, H., Liang, Z., Zhou, C., Zeng, Z., Wang, F., Hu, T., He, X., Wu, X., Wu, X., & Lan, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00534-2 · Cited by 104
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · Cancers · doi:10.3390/cancers13215557 · Cited by 101
Xu, R.-Y., Song, J., Ruze, R., Chen, Y., Yin, X., Wang, C., & Zhao, Y.-P. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05987-7 · Cited by 98
Drug resistance induces the upregulation of H2S-producing enzymes in HCT116 colon cancer cells
Untereiner, A. A., Pavlidou, A., Druzhyna, N., Papapetropoulos, A., Hellmich, M. R., & Szabó, C. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.10.007 · Cited by 98
Glutaminase isoenzymes in the metabolic therapy of cancer
Matés, J. M., Campos-Sandoval, J. A., & Márquez, J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.007 · Cited by 99
Zhou, R., Pantel, A. R., Li, S., Lieberman, B. P., Plöessl, K., Choi, H., Blankemeyer, E. R., Lee, H. S., Kung, H. F., Mach, R. H., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1945 · Cited by 99
Tang, X., Keenan, M. M., Wu, J., Lin, C.-A., Dubois, L. G., Thompson, J. W., Freedland, S. J., Murphy, S. K., & Chi, J. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005158 · Cited by 95
Li, D., Fu, Z., Chen, R., Zhao, X., Zhou, Y., Zeng, B., Yu, M., Zhou, Q., Lin, Q., Gao, W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5150 · Cited by 100
Liu, M., Quek, L., Sultani, G., & Turner, N. A. (2016) · Cancer & Metabolism · doi:10.1186/s40170-016-0160-x · Cited by 100
Aguilar, E., de Mas, I. M., Zodda, E., Marín, S., Morrish, F. M., Selivanov, V. A., Meca‐Cortés, Ó., Delowar, H., Pons, M., Izquierdo, I., et al. (2016) · Stem Cells · doi:10.1002/stem.2286 · Cited by 97
Abrego, J., Gunda, V., Vernucci, E., Shukla, S. K., King, R. J., Dasgupta, A., Goode, G. D., Murthy, D., Yu, F., & Singh, P. K. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.029 · Cited by 96
Chemical Basis for Deuterium Labeling of Fat and NADPH
Zhang, Z., Chen, L., Лиу, Л., Su, X., & Rabinowitz, J. D. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08012 · Cited by 101
Metabolic Plasticity of Tumor Cell Mitochondria
Cannino, G., Ciscato, F., Masgras, I., Sànchez‐Martìn, C., & Rasola, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00333 · Cited by 97
Glutamine Metabolism in Brain Tumors
Natarajan, S. K., & Venneti, S. (2019) · Cancers · doi:10.3390/cancers11111628 · Cited by 99
Zhang, Y., Xu, Y., Lu, W., Ghergurovich, J. M., Guo, L., Blair, I. A., Rabinowitz, J. D., & Yang, X. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.002 · Cited by 96
Harding, J. J., Telli, M. L., Münster, P. N., Voss, M. H., Infante, J. R., DeMichele, A. M., Dunphy, M. P., Le, M. H., Molineaux, C., Orford, K. W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1204 · Cited by 98
Lanning, N. J., Looyenga, B. D., Kauffman, A. L., Niemi, N. M., Sudderth, J., DeBerardinis, R. J., & MacKeigan, J. P. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.065 · Cited by 94
Targeting Pancreatic Ductal Adenocarcinoma Acidic Microenvironment
Cruz‐Monserrate, Z., Roland, C. L., Deng, D., Arumugam, T., Moshnikova, A., Andreev, O. A., Reshetnyak, Y. K., & Logsdon, C. D. (2014) · Scientific Reports · doi:10.1038/srep04410 · Cited by 94
Ji, S., Qin, Y., Liang, C., Huang, R., Shi, S., Liu, J., Jin, K., Liang, D., Xu, W., Zhang, B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2380 · Cited by 94
Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis
Wahl, D. R., Dresser, J., Wilder-Romans, K., Parsels, J. D., Zhao, S. G., Davis, M. A., Zhao, L., Kachman, M. T., Wernisch, S., Burant, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2008 · Cited by 97
Self-citationVitamin B6 Addiction in Acute Myeloid Leukemia
Chen, C.-C., Li, B., Millman, S. E., Chen, C., Li, X., Morris, J. P., Mayle, A., Ho, Y.-J., Loizou, E., Liu, H., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.002 · Cited by 95
Metadata
- Authors
- Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., Kang, Y., Fleming, J. B., Bardeesy, N., Asara, J. M., Haigis, M. C., DePinho, R. A., Cantley, L. C., & Kimmelman, A. C.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Massachusetts General Hospital (US)
- Harvard University (US)
- Corresponding author
- Cantley, Lewis C.
- Kimmelman, Alec C.
- ORCID
- Venue
- Nature
- Published
- 2013-03-27
- Volume
- 496
- Issue
- 7443
- Pages
- 101-105
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3656466
- OpenAlex
- W2014988241
- Cited by
- 1,990
- References
- 27
- Citations by year
- 2026: 130 · 2025: 143 · 2024: 138 · 2023: 169 · 2022: 193 · 2021: 209 · 2020: 169 · 2019: 162 · 2018: 141 · 2017: 144 · 2016: 152 · 2015: 112 · 2014: 95 · 2013: 31
- FWCI
- 45.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2013-06-12)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (T32CA009382, R01CA157490, P01CA120964, P01CA117969, P30CA006516)
- National Institute of General Medical Sciences (R01GM056203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- pancreatic ductal adenocarcinoma, glutamine metabolism, KRAS, tumor metabolic reprogramming, oxaloacetate, NADPH/NADP+ ratio, redox homeostasis, glutamine deprivation, reactive oxygen species, glutathione, tumor growth
- MeSH terms
- Adenocarcinoma, Aspartate Aminotransferases, Citric Acid Cycle, Glutamate Dehydrogenase, Glutamine, Homeostasis, Humans, Ketoglutaric Acids, Oncogenes, Oxidation-Reduction, Pancreatic Neoplasms, Proto-Oncogene Proteins, Oncogene Protein p21(ras), Proto-Oncogene Proteins p21(ras), Reactive Oxygen Species, ras Proteins, Cell Line, Tumor, Cell Proliferation, Metabolic Networks and Pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
